Novavax Inc. (NVAX)
Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer John Trizzino - President and Chief Operating Officer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank of America Securities Tom Shrader - BTIG Eric Joseph - JPMorgan Chris LoBianco - TD Securities Operator Good morning and welcome to Novavax First Quarter 2025 Financial Results and Operational Highlights Conference Call.
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago.
Novavax to Report First-Quarter Earnings: Is a Beat in Store?
On NVAX's first-quarter earnings call, investors will likely focus on pipeline updates.
Novavax (NVAX) Flat As Market Gains: What You Should Know
In the most recent trading session, Novavax (NVAX) closed at $6.41, indicating no shift from the previous trading day.
Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Novavax shares jump as FDA signals path to COVID vaccine approval
Novavax, Inc. (NASDAQ:NVAX) shares surged more than 16% after the company shared a positive update on its COVID-19 vaccine, which it believes is “approvable” based on its conversations with the US Food and Drug Administration (FDA). The company said the FDA has requested additional data on the vaccine as part of a post-marketing commitment (PMC).
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
FDA asks Novavax for commitment on post-approval studies for COVID vaccine
Novavax said on Wednesday the U.S. Food and Drug Administration has sought a commitment from the COVID-19 vaccine maker for additional clinical data if it approves the shot.
Why the Market Dipped But Novavax (NVAX) Gained Today
Novavax (NVAX) closed at $6.01 in the latest trading session, marking a +0.17% move from the prior day.
Here's Why Novavax (NVAX) Fell More Than Broader Market
In the latest trading session, Novavax (NVAX) closed at $6.39, marking a -0.31% move from the previous day.
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab
The decline in Novavax stock follows the HHS Secretary's concerns regarding the efficacy of its protein-based COVID-19 vaccine in a recent interview.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
